Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

被引：0

作者：

Lin, Jessica Jiyeong

Tan, Daniel Shao-Weng

Kummar, Shivaani

Patel, Jyoti D.

Cermignani, Luciano

Dai, Ming-Shen

Lassen, Ulrik Niels

Leyvraz, Serge

Liu, Yongmei

Moreno, Victor

Rosen, Lee S.

Saada-Bouzid, Esma

Solomon, Benjamin Maurice

Xu, Rui-Hua

Yachnin, Jeffrey

Norenberg, Ricarda

Burcoveanu, Domnita-Ileana

Mussi, Chiara E.

Shen, Lin

Drilon, Alexander E.

机构：

[1] Massachusetts Gen Hosp, Dept Med, Boston, MA USA

[2] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[3] Duke NUS Med Sch, Singapore, Singapore

[4] Oregon Hlth & Sci Univ, Portland, OR USA

[5] Northwestern Univ, Chicago, IL USA

[6] Hosp Aleman, Buenos Aires, Argentina

[7] Tri Serv Gen Hosp, Taipei, Taiwan

[8] Rigshosp, Dept Oncol, Copenhagen, Denmark

[9] Charite Univ Med Berlin, Berlin, Germany

[10] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China

[11] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China

[12] START MADRID FJD, Hosp Fdn Jimenez Diaz, Madrid, Spain

[13] UCLA, Div Hematol Oncol, Santa Monica, CA USA

[14] Univ Cote Dazur, Ctr Antoine Lacassagne, Nice, France

[15] Avera Canc Inst, Sioux Falls, SD USA

[16] Sun Yat Sen Univ, State Key Lab, Canc Ctr, Guangzhou, Peoples R China

[17] Karolinska Univ Hosp, Stockholm, Sweden

[18] Chrestos Concept GmbH & Co KG, Essen, Germany

[19] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland

[20] Bayer SpA, Milan, Italy

[21] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China

[22] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9056

引用

页数：1

共 50 条

[31] Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Federman, Noah
McDermott, Ray
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (10) : 931 - 939
[32] Activity of Larotrectinib in Tropomyosin Receptor Kinase Fusion Lung Cancer
Farago, A. F.
Kummar, S.
Moreno, V.
Patel, J.
Lassen, U.
Rosen, L.
Childs, B. H.
Hyman, D. M.
Drilon, A.
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S28 - S28
[33] Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer
Rosen, Ezra Y.
Italiano, Antoine
Juric, Dejan
Reeves, John A.
Dima, Laura
Brega, Nicoletta
Drilon, Alexander
CANCER RESEARCH, 2021, 81 (04)
[34] Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Qi, Changsong
Shen, Lin
Andre, Thierry
Chung, Hyun Cheol
Cannon, Timothy L.
Garralda, Elena
Italiano, Antoine
Rieke, Damian T.
Liu, Tianshu
Burcoveanu, Domnita-Ileana
Neu, Natascha
Mussi, Chiara E.
Xu, Rui-Hua
Hong, David S.
Drilon, Alexander
Berlin, Jordan
EUROPEAN JOURNAL OF CANCER, 2025, 220
[35] Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Berlin, Jordan
Hong, David S.
Deeken, John F.
Boni, Valentina
Oh, Do-Youn
Patel, Jyoti D.
Nanda, Shivani
Brega, Nicoletta
Childs, Barrett H.
Hyman, David Michael
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[36] Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Leyvraz, S.
Berlin, J.
Hong, D. S.
Deeken, J.
Valentina, B.
Oh, D. -Y.
Patel, J.
Nanda, S.
Brega, N.
Childs, B. H.
Hyman, D. M.
Drilon, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 231 - 232
[37] Larotrectinib Efficacy and Safety in Pediatric Patients with TRK Fusion Cancer
Koga, Yuhki
PEDIATRIC BLOOD & CANCER, 2020, 67
[38] LAROTRECTINIB EFFICACY AND SAFETY IN PEDIATRIC PATIENTS WITH TRK FUSION CANCER
Albert, Catherine
Geoerger, Birgit
van Tilburg, Cornelis
DuBois, Steven
Federman, Noah
Nagasubramanian, Ramamoorthy
Doz, Francois
Orbach, Daniel
Bielack, Stefan
Shukla, Neerav
Turpin, Brian
Casanova, Michela
Spunt, Sheri
Nanda, Shivani
Childs, Barrett
Pappo, Alberto
Laetsch, Theodore
Mascarenhas, Leo
PEDIATRIC BLOOD & CANCER, 2020, 67 : S10 - S11
[39] Larotrectinib Efficacy and Safety in Pediatric Patients with TRK Fusion Cancer
Geoerger, B.
van Tilburg, C.
DuBois, S.
Albert, C.
Federman, N.
Nagasubramanian, R.
Doz, F.
Orbach, D.
Bielack, S.
Shukla, N.
Turpin, B.
Casanova, M.
Spunt, S.
Qamoos, H.
Cox, M.
Nanda, S.
Childs, B.
Pappo, A.
Laetsch, T.
Mascarenhas, L.
PEDIATRIC BLOOD & CANCER, 2019, 66 : S65 - S66
[40] Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC)
Cabanillas, Maria E.
Lin, Jessica Jiyeong
Brose, Marcia S.
McDermott, Raymond S.
Almubarak, Mohammed
Bauman, Jessica R.
Casanova, Michela
Kummar, Shivaani
Lee, Se-Hoon
Leyvraz, Serge
Oh, Do-Youn
Shen, Lin
Neu, Natascha
Bernard-Gauthier, Vadim
Mussi, Chiara E.
Hong, David S.
Drilon, Alexander E.
Waguespack, Steven G.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →